Drug Trial Radar · NCT02559492
Itacitinib Combined With INCB024360 and/or Itacitinib Combined With INCB050465 in Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Sep 25, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
142
Actual
Start
Nov 2015
Primary completion
Sep 10, 2018
Study completion Aug 18, 2019
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Sep 24, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, Phase 1b, platform study in subjects with advanced or metastatic solid tumors. The study will be divided into 3 parts (Part 1a, Part 1b, and Part 2). Part 1a will evaluate a JAK inhibitor with JAK1 selectivity (Itacitinib) in combination with an IDO1 inhibitor (epacadostat; INCB024360; Group A) and Itacitinib in combination with a PI3K-delta inhibitor (INCB050465; Group B) to determine the MTD or PAD and the recommended Part 1b doses for each combination. Once the recommended dose has been identified for each treatment group in Part 1a, subjects with advanced solid tumors will be enrolled into expansion cohorts based upon prior treatment history with a PD-1 pathway-targeted agent (Part 1b). In Part 2, additional expansion cohorts will be enrolled to further evaluate lower doses of itacitinib and INCB050465 in subjects with select tumor types.
Conditions
- Solid Tumors
Interventions
ItacitinibDrug
Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
EpacadostatDrug
Epacadostat tablets will be administered orally, twice daily.
ItacitinibDrug
Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
INCB050465Drug
INCB050465 tablets will be administered orally once daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Baseline through 21 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Duarte, California
Site not named
Denver, Colorado
Site not named
New Haven, Connecticut
Site not named
Tampa, Florida
Site not named
Chicago, Illinois
Site not named
Rochester, Minnesota
Site not named
Huntersville, North Carolina
Site not named
Nashville, Tennessee
Site not named
Dallas, Texas
Site not named
Houston, Texas
Site not named
Salt Lake City, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.